Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET scan could better spot tumors in kids with cancer

NCT ID NCT00840047

Diagnosis Sponsor: St. Jude Children's Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a special PET scan using a radioactive form of methionine (a natural amino acid) can help doctors see tumors in children and young adults with various cancers, including brain tumors and sarcomas. About 503 participants will be scanned to see if the method works for detecting tumors, checking treatment response, and telling leftover tumor from scar tissue. The goal is to improve how doctors diagnose and monitor cancer without invasive procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

503 people

The number who actually took part.

Started

Jul 2009

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All participants under the care of St. Jude physicians with known or suspected neoplastic disease are eligible for participation. * Participants will have had, or are scheduled to have clinical imaging evaluations which may include FDG PET CT, or CT, or MRI within 4 weeks of entry. * No limit on age or gender. * Female participants of childbearing age must not be lactating due to theoretical potential harm to the infant from exposure to radiation. * Informed consent signed by participant, parent, or guardian according to the guidelines of the institutional review board. Exclusion Criteria: * More than 6 MET PET scans within the previous 12 months. * Inability or unwillingness of research participant, parent, or legal guardian/representative to give written informed consent. Inclusion Criteria for Open-Access * All participants under the care of St. Jude physicians with known or suspected neoplastic disease are eligible for participation. * No limit on age or gender * Female participants of childbearing age must not be lactating due to theoretical potential harm to the infant from exposure to radiation. * Informed consent signed by participant, parent, or guardian according to the guidelines of the institutional review board. Exclusion Criteria for Open-Access * More than 6 MET PET scans within the previous 12 months. * Inability or unwillingness of research participant, parent, or legal guardian/representative to give written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain stem glioma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain stem glioma craniopharyngioma ependymoma Ewing sarcoma Hodgkins lymphoma medulloblastoma neuroblastoma non-Hodgkin lymphoma osteosarcoma rhabdomyosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain stem glioma Brain tumors and/or solid tumors including Craniopharyngioma Ependymoma Ewing sarcoma High grade CNS tumors Hodgkin lymphoma Low grade CNS tumors Medulloblastoma Neuroblastoma Non-Hodgkin lymphoma Osteosarcoma OTHER Rhabdomyosarcoma

Contacts and locations

Locations

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38119, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.